Jaypirca: what changed in the evidence · Jaypirca · 2023 – 2026

How do Jaypirca's four FDA decisions compare, side by side?

Population, trial, design, comparator, endpoint, result and regulatory basis for each decision, quoted from the FDA. The first two are single-arm and response-based; the last two are randomized against chemoimmunotherapy-based comparators and measure progression-free survival.

EphemerisX Research · Published October 8, 2026 · 10 source documents · 1 min read

Short answer

Two pairs. The 2023 decisions share a study (BRUIN), a design (single-arm), an endpoint (response rate) and a basis (accelerated approval). The 2025 and 2026 decisions each rest on their own randomized, open-label trial against a rituximab-based comparator, with progression-free survival assessed by an independent committee, and neither carries accelerated-approval terms. The table sets out each decision in the FDA's words.

What the evidence shows

Each cell quotes the FDA's announcement, letter or label for that decision. The populations narrow and widen: the two accelerated approvals cover patients after at least two prior lines; the traditional approval covers patients treated with a covalent BTK inhibitor; the 2026 approval covers untreated patients without 17p deletion.

Not in this record: a trial comparing the two randomized studies with each other; they enrolled different populations against different comparators. Whether the evidence accumulated: Did each approval build on the last, or rest on a new body of evidence?

Jaypirca's four FDA decisions, in the FDA's words

	MCL, Jan 2023	CLL/SLL, Dec 2023	R/R CLL/SLL, Dec 2025	Untreated CLL/SLL, Oct 2026
Population	after at least two lines of systemic therapy, including a BTK inhibitor FDA · Jan 27, 2023 · p. 1	at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor FDA · Dec 1, 2023 · p. 1	previously been treated with a covalent BTK inhibitor FDA · Dec 3, 2025 · p. 1	previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion FDA · Oct 2, 2026 · p. 1
Trial and design	single-arm trial of pirtobrutinib monotherapy that included 120 patients FDA · Jan 27, 2023	single-arm, multicohort trial that included 108 patients FDA · Dec 1, 2023	a randomized, open-label, active-controlled trial. The trial randomized 238 patients FDA · Dec 3, 2025	a randomized, open-label, active-controlled trial in 282 patients FDA · Oct 2, 2026
Comparator	None (single-arm)	None (single-arm)	investigator’s choice of idelalisib plus a rituximab product (IR) or bendamustine plus a rituximab product (BR) FDA · Dec 3, 2025	bendamustine plus a rituximab product (n=141) for six cycles FDA · Oct 2, 2026
Endpoint	overall response rate (ORR) and duration of response (DOR) FDA · Jan 27, 2023	overall response rate (ORR) and duration of response (DOR) FDA · Dec 1, 2023	The primary efficacy outcome measure was progression-free survival (PFS) FDA · Dec 3, 2025	The main efficacy outcome measure was progression-free survival (PFS) FDA · Oct 2, 2026
Result	The ORR was 50% (95% CI: 41, 59) FDA · Jan 27, 2023	The ORR was 72% (95% CI: 63, 80) FDA · Dec 1, 2023	Hazard ratio 0.58 [95% CI: 0.38, 0.89] FDA · Dec 3, 2025	Hazard ratio 0.20 [95% CI: 0.11, 0.37] FDA · Oct 2, 2026
Basis	approved under accelerated approval based on response rate FDA · Jan 27, 2023 · p. 3	approved under accelerated approval based on response rate FDA · Dec 1, 2023 · p. 3	conversion from accelerated approval to traditional approval FDA · Dec 3, 2025 · p. 1	The FDA's October 2, 2026 approval letter does not mention accelerated approval, a confirmatory trial or a postmarketing requirement. FDA · searched

Follow the thread

What evidence did the FDA rely on when Jaypirca first received accelerated approval?ORR 50%
What evidence allowed the FDA to convert Jaypirca's CLL/SLL approval to traditional approval?Hazard ratio 0.58
What did the CLL/SLL confirmatory trial show beyond progression-free survival?Investigator's choice IR or BR
What evidence supported Jaypirca's approval in previously untreated CLL/SLL?Hazard ratio 0.20

The documents, by date

The passages quoted

FDA announcement, January 27, 2023

The main efficacy measures were overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee using Lugano criteria. The ORR was 50% (95% CI: 41, 59) with a complete response rate of 13%. The estimated median DOR was 8.3 months (95% CI: 5.7, NE), and the estimated DOR rate at 6 months was 65.3% (95% CI: 49.8, 77.1).